PHARMACOLOGIC CHARACTERISTICS OF 1-(ORTHO-TOLUOXY)-2,3-BIS-(2,2,2-TRICHLORO-1-HYDROXYETHOXY)-PROPANE

¹ Warner Institute for Therapeutic Research, New York, New York
² Research Laboratories, Nepera Chemical Company, Inc., Yonkers, New York
³ Bristol Myers, Products Division, Hillside, N. J.

1. Compound # 1318 (1-(ortho-toluoxy)-2,3-bis-(2,2,2-trichloro-1-hydroxy-ethoxy)-propane) had low toxicity in the mouse, rat and guinea pig.

2. Chronic toxicity studies conducted on weanling rats over a period of two months were negative with respect to growth, hematology and organ pathology.

3. Large doses of # 1318 induced hypnosis rapidly. The duration of action was intermediate between that induced by moderate-, and long-acting barbiturates.

4. Small doses, insufficient to cause outward signs of depression, significantly prolonged the period of sleep induced by hexobarbital.

5. Compound # 1318 antagonized convulsions induced by pentylenetetrazole.

6. Surgical implantation of crystalline # 1318 into the stomach caused no gastric irritation.

7. The drug exhibited no effect on blood pressure or respiration in anesthetized dogs.

8. It displayed no analgesic activity.

9. It had no effect on the isolated ileum or uterus, and similarly negative findings were noted when # 1318 was perfused through the isolated mammalian heart.

10. Pentylenetetrazole completely antagonized the effects of overdosage with # 1318. Other analeptic drugs afforded only temporary relief under our experimental conditions.